This in turn recruits and activates antigen-presenting cells (APCs), which initiate an anticancer immune response when they migrate to the tumor draining lymph nodes and cross-activate CD8+ cytotoxic T lymphocytes (CTLs) (20). This evidence concerns the gene CD8A and neoplasm.